Skip to main
GUTS

GUTS Stock Forecast & Price Target

GUTS Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Fractyl Health Inc. is positioned favorably within the growing metabolic therapeutics market, as evidenced by a staggering 587% increase in GLP-1 drug prescriptions from 2019 to 2024, indicating a rising acknowledgment of effective treatments for obesity and type 2 diabetes. The company's innovative approach, exemplified by the anticipated advancements in its first-in-human Phase 1 trial and scalable manufacturing capabilities, suggests a promising pathway toward significant market penetration, with updated models projecting a peak penetration of Revita to 2%. Furthermore, the positive REMAIN-1 trial data highlights the potential of GLP-1 PGTx not only to improve blood glucose and weight control compared to existing therapies but also to provide benefits in lipid profiles and cardiovascular risk factors, underscoring its strategic advantage in addressing multiple facets of metabolic disease.

Bears say

Fractyl Health faces significant challenges regarding its financial outlook, primarily due to a high cash burn rate associated with its development and commercial programs, which may not be adequately offset by potential milestone revenue payments. Additionally, the gradual loss of β-cell function in type 2 diabetes patients raises concerns about the long-term efficacy of Fractyl's therapeutic interventions, particularly related to insulin production and control of hyperglycemia. The potential inability to secure sufficient capital to advance its Revita and Rejuva platforms further contributes to a negative outlook on the company’s financial stability and growth prospects.

GUTS has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fractyl Health Inc (GUTS) Forecast

Analysts have given GUTS a Strong Buy based on their latest research and market trends.

According to 4 analysts, GUTS has a Strong Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fractyl Health Inc (GUTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.